Litigation Details for In re: Entresto (Sacubitril/Valsartan) Patent Litigation (D. Del. 2020)
✉ Email this page to a colleague
In re: Entresto (Sacubitril/Valsartan) Patent Litigation (D. Del. 2020)
| Docket | ⤷ Sign Up | Date Filed | 2020-03-27 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | Defendant | Referred To | |
| Patents | 10,004,746; 10,010,507; 10,016,435; 10,106,548; 10,125,140; 10,213,386; 10,294,231; 10,294,232; 10,335,462; 7,342,117; 7,468,390; 7,514,444; 7,879,828; 7,982,049; 8,008,309; 8,101,659; 8,404,744; 8,476,284; 8,497,277; 8,563,563; 8,679,069; 8,697,711; 8,703,780; 8,735,403; 8,754,090; 8,754,091; 8,796,331; 8,877,938; 8,952,015; 8,957,079; 8,999,999; 9,125,889; 9,181,257; 9,296,753; 9,388,134; 9,540,382; 9,655,857; 9,713,617; 9,725,455; 9,795,604; 9,801,881; 9,801,883; 9,814,721 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in In re: Entresto (Sacubitril/Valsartan) Patent Litigation
Details for In re: Entresto (Sacubitril/Valsartan) Patent Litigation (D. Del. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2019-03-01 | 1 | Complaint | PageID #: 2 Patent”); 9,655,857 (“the ’857 Patent”); 9,725,455 (“the ’455 Patent”); 10,010,507 (“the ’507… United States Patent Nos. 7,514,444 (“the ’444 Patent”); 8,008,309 (“the ’309 Patent”); 8,476,284 (“…(“the ’284 Patent”); 8,497,277 (“the ’277 Patent”); 8,697,711 (“the ’711 Patent”); 8,735,403 (“the ’403…’403 Patent”); 8,754,090 (“the ’090 Patent”); 8,754,091 (“the ’091 Patent”); 8,952,015 (“the ’015 Patent…507 Patent”); 10,106,548 (“the ’548 Patent”); and 10,125,140 (“the ’140 Patent”). | External link to document |
| 2023-06-01 | 1057 | Proposed Order | pediatric exclusivity for U.S. Patent No. 8,404,744 (“the ’744 patent”) expires on July 14, 2023, which… patent or the ’667 patent] [Noratech’s proposal: if such deposition concerned the ’659 patent or… proposal: the validity of] the ’659 patent or the ’667 patent, (ii) Novartis’s documents concerning…proposal: the validity of] the ’659 patent or the ’667 patent, and (iii) the deposition testimony (including…Asserted Patent. Novartis will produce to Noratech the file history for the ’659 and ’667 patents within | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
